NCT00545389View on ClinicalTrials.gov

Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476

PHASE2CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

February 10, 2003

Primary Completion Date

October 20, 2004

Study Completion Date

October 20, 2004

Conditions

Colitis, Ulcerative

Interventions

DRUG

SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

Trial Locations (1)

Unknown

Imelda General Hospital, Bonheiden

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Shire

INDUSTRY